CA
NZ
UK
AU
IND
US
…
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops INS1201, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as it is also developing pre-clinical research programs for gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. In addition, it provides INS1148, monoclonal antibody targeting stem cell factor called SCF248 that is in phase-2 clinical trial for the treatment of interstitial lung disease, and asthma; and INS1202, an intrathecally delivered gene therapy which is in phase 1 of clinical trial for the treatment of amyotrophic lateral sclerosis. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Insmed Inc develops therapies for rare pulmonary and infectious diseases; its lead product Arikayce (amikacin liposome inhalation suspension) is FDA‑approved for refractory Mycobacterium avium complex lung disease and drives current revenues. Long-term growth drivers may include expanded indications and geographic rollout of Arikayce, broader physician adoption, and advancement of pipeline candidates for non‑tuberculous mycobacterial and other rare respiratory diseases.
Principal risks include product concentration on Arikayce, clinical and regulatory execution risk for pipeline programs, pricing and reimbursement pressure, manufacturing complexity for liposomal inhalation products, and competitive or exclusivity challenges.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -1271.75M | -910.07M | -747.01M | -480.15M | -436.41M |
| Net income | -1276.78M | -913.77M | -749.57M | -481.53M | -434.65M |
| Selling general administrative | 701.17M | 461.12M | 344.50M | 244.98M | 234.27M |
| Selling and marketing expenses | - | - | - | 20.80M | - |
| Gross profit | 481.55M | 277.96M | 239.63M | 190.23M | 144.31M |
| Reconciled depreciation | 16.45M | 11.01M | 10.58M | 10.33M | 14.18M |
| Ebit | -1187.95M | -829.81M | -670.76M | -478.12M | -367.76M |
| Ebitda | -1171.50M | -818.79M | -660.18M | -458.21M | -373.37M |
| Depreciation and amortization | 16.45M | 11.01M | 10.58M | 19.92M | -5.61M |
| Non operating income net other | - | - | - | 3.62M | -20.84M |
| Operating income | -1176.73M | -878.25M | -709.63M | -478.12M | -367.76M |
| Other operating expenses | 1783.15M | 1241.96M | 1014.83M | 723.48M | 556.22M |
| Interest expense | 83.80M | 84.91M | 81.69M | 26.45M | 40.47M |
| Tax provision | 5.03M | 3.71M | 2.56M | 1.38M | -1.76M |
| Interest income | 0.00M | 2.23M | 1.88M | - | - |
| Net interest income | -83.80M | -84.91M | -81.69M | -26.45M | -40.47M |
| Income tax expense | 5.03M | 3.71M | 2.56M | 1.38M | -1.76M |
| Total revenue | 606.42M | 363.71M | 305.21M | 245.36M | 188.46M |
| Total operating expenses | 1658.28M | 1156.22M | 949.26M | 668.36M | 512.07M |
| Cost of revenue | 124.88M | 85.74M | 65.57M | 55.13M | 44.15M |
| Total other income expense net | -95.02M | -31.81M | -37.39M | -2.03M | -68.65M |
| Net income from continuing ops | -1276.78M | -913.77M | -749.57M | -481.53M | -434.65M |
| Net income applicable to common shares | - | - | - | -481.53M | -434.65M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 2264.56M | 2025.23M | 1329.84M | 1656.43M | 1243.51M |
| Intangible assets | 97.65M | 58.65M | 63.70M | 68.76M | 73.81M |
| Other current assets | 91.24M | 37.24M | 24.18M | 25.47M | 28.90M |
| Total liab | 1525.58M | 1739.85M | 1661.76M | 1568.48M | 833.04M |
| Total stockholder equity | 738.98M | 285.38M | -331.92M | 87.95M | 410.47M |
| Deferred long term liab | - | - | - | 37.59M | 72.04M |
| Other current liab | 369.70M | 208.00M | 214.99M | 131.66M | 89.25M |
| Common stock | 2.14M | 1.79M | 1.48M | 1.36M | 1.19M |
| Capital stock | 2.14M | 1.79M | 1.48M | 1.36M | 1.19M |
| Retained earnings | -5636.69M | -4359.92M | -3446.14M | -2696.58M | -2265.24M |
| Other liab | - | - | - | 60.49M | 95.74M |
| Good will | 136.11M | 136.11M | 136.11M | 136.11M | 136.11M |
| Other assets | - | - | - | 113.69M | 50.99M |
| Cash | 510.44M | 555.03M | 482.37M | 1074.04M | 716.78M |
| Total current liabilities | 468.87M | 297.53M | 225.63M | 190.24M | 135.17M |
| Current deferred revenue | - | -12.32M | -65.39M | - | - |
| Net debt | 257.71M | 759.09M | 721.62M | 103.83M | -104.51M |
| Short term debt | 19.26M | 16.50M | 10.64M | 8.13M | 10.14M |
| Short long term debt total | 768.16M | 1314.12M | 1203.99M | 1177.87M | 612.27M |
| Other stockholder equity | 6372.06M | 4645.79M | 3113.49M | 2782.42M | 2673.56M |
| Property plant equipment | - | - | - | 56.49M | 52.95M |
| Total current assets | 1794.21M | 1621.66M | 929.06M | 1273.38M | 837.04M |
| Long term investments | - | - | - | 0.00M | 50.04M |
| Net tangible assets | - | - | - | -116.92M | 200.55M |
| Short term investments | 919.60M | 878.80M | 298.07M | 74.24M | - |
| Net receivables | 140.86M | 52.01M | 41.19M | 29.71M | 24.35M |
| Long term debt | 540.96M | 1103.38M | 1155.31M | 1125.25M | 566.59M |
| Inventory | 132.07M | 98.58M | 83.25M | 69.92M | 67.01M |
| Accounts payable | 79.91M | 73.03M | 65.39M | 50.46M | 35.78M |
| Accumulated other comprehensive income | 1.46M | -2.29M | -0.74M | 0.76M | 0.97M |
| Common stock total equity | - | - | - | 1.36M | 1.19M |
| Retained earnings total equity | - | - | - | -2696.58M | -2265.24M |
| Non currrent assets other | 97.38M | 93.23M | 96.57M | 76.10M | 50.99M |
| Non current assets total | 470.35M | 403.57M | 400.77M | 383.05M | 406.47M |
| Capital lease obligations | 45.71M | 45.49M | 48.68M | 52.62M | 45.68M |
| Long term debt total | - | - | - | 1125.25M | 566.59M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -2.01M | -583.17M | -205.10M | -34.58M | -50.29M |
| Change to liabilities | - | - | - | 50.01M | -7.58M |
| Total cashflows from investing activities | -64.58M | -583.17M | -223.60M | -34.58M | -64.28M |
| Net borrowings | -4.93M | 147.39M | -1.22M | 332.22M | 321.70M |
| Total cash from financing activities | 954.07M | 1341.02M | 168.44M | 793.27M | 612.55M |
| Change to operating activities | - | - | - | -35.30M | -25.43M |
| Net income | -1276.78M | -913.77M | -749.57M | -481.53M | -434.65M |
| Change in cash | -44.59M | 72.66M | -591.66M | 357.25M | 184.03M |
| Begin period cash flow | 555.03M | 482.37M | 1074.04M | 716.78M | 532.76M |
| End period cash flow | 510.44M | 555.03M | 482.37M | 1074.04M | 716.78M |
| Total cash from operating activities | -935.01M | -683.88M | -536.25M | -400.44M | -363.30M |
| Issuance of capital stock | 823.28M | 1084.12M | 296.78M | 292.15M | 269.89M |
| Depreciation | 16.45M | 11.01M | 10.58M | 10.33M | 14.18M |
| Other cashflows from investing activities | -30.00M | - | 3.42M | - | -6.70M |
| Change to inventory | -31.52M | -17.04M | -13.61M | -1.71M | -17.46M |
| Change to account receivables | -88.31M | -12.93M | -11.96M | -6.42M | -8.12M |
| Sale purchase of stock | - | - | - | 311.66M | 291.92M |
| Other cashflows from financing activities | - | 109.51M | 17.18M | 501.12M | 567.66M |
| Change to netincome | - | - | - | 46.26M | 71.04M |
| Capital expenditures | 32.56M | 21.92M | 13.29M | 9.88M | 7.29M |
| Change receivables | - | - | - | -6.42M | -8.12M |
| Cash flows other operating | - | - | - | -21.36M | 19.27M |
| Cash and cash equivalents changes | - | - | - | 358.25M | 184.96M |
| Change in working capital | -80.30M | -3.18M | -39.22M | 6.58M | -58.58M |
| Stock based compensation | 152.71M | 96.83M | 74.78M | 57.69M | 46.02M |
| Other non cash items | 252.90M | 125.22M | 167.18M | 6.50M | 52.04M |
| Free cash flow | -967.58M | -705.80M | -549.53M | -410.32M | -370.59M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| INSM Insmed Inc |
2.02 2.13% |
96.98 | - | 77.52 | 23.02 | 36.12 | 23.54 | -6.05 |
| NVO Novo Nordisk A/S |
-0.38 0.98% |
38.29 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
8.66 1.66% |
529.69 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-2.83 0.35% |
813.27 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
790.15 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops INS1201, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as it is also developing pre-clinical research programs for gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. In addition, it provides INS1148, monoclonal antibody targeting stem cell factor called SCF248 that is in phase-2 clinical trial for the treatment of interstitial lung disease, and asthma; and INS1202, an intrathecally delivered gene therapy which is in phase 1 of clinical trial for the treatment of amyotrophic lateral sclerosis. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
700 US Highway 202/206, Bridgewater, NJ, United States, 08807
908 977 9900
1664
| Name | Title | Year Born |
|---|---|---|
| Mr. William H. Lewis J.D., M.B.A. | Pres, CEO & Chairman | 1969 |
| Ms. Sara M. Bonstein MBA | Chief Financial Officer | 1981 |
| Mr. Roger Adsett | Chief Operating Officer | 1969 |
| Ms. S. Nicole Schaeffer | Chief People Strategy Officer | 1968 |
| Dr. Martina Flammer M.B.A., M.D. | Chief Medical Officer | 1964 |
| Mr. John Goll III | Sr. VP & Chief Accounting Officer | NA |
| Eleanor Barisser | Associate Director of Investor Relations | NA |
| Mr. Michael Alexander Smith | Sr. VP & Gen. Counsel | 1978 |
| Mandy Fahey | Exec. Director of Corp. Communications | NA |
| Mr. John Drayton Wise | Sr. VP, Head of United States & Chief Commercial Officer | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+0.02%
Communication Services
-0.63%
Consumer Cyclical
-0.11%
Consumer Defensive
-0.45%
Energy
+0.39%
Financial Services
-0.10%
Financials
-0.81%
Healthcare
+1.03%
Industrials
+0.32%
Real Estate
-0.31%
Technology
+0.59%
Utilities
-0.18%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...